Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study

被引：0
|
作者：
Luigi Celio
Diego Cortinovis
Alessio Aligi Cogoni
Luigi Cavanna
Olga Martelli
Simona Carnio
Elena Collovà
Federica Bertolini
Fausto Petrelli
Alessandra Cassano
Rita Chiari
Francesca Zanelli
Salvatore Pisconti
Isabella Vittimberga
Antonietta Letizia
Andrea Misino
Angela Gernone
Erminio Bonizzoni
Sara Pilotto
Sabino De Placido
Emilio Bria
机构：
[1] Desenzano del Garda Hospital,Medical Oncology Unit, ASST del Garda
[2] ASST Monza San Gerardo Hospital,Medical Oncology Department
[3] Azienda Ospedaliero-Universitaria di Sassari,Medical Oncology Department
[4] Azienda Ospedaliera di Piacenza,Oncology Department
[5] ASL Frosinone,Medical Oncology
[6] San Luigi Gonzaga Hospital,Department of Oncology
[7] University of Turin,Cancer Centre Department – Oncology Unit
[8] ASST Ovest Milanese – Legnano Hospital,Department of Oncology and Hematology
[9] AOU Policlinico di Modena,Medical Oncology Unit
[10] ASST Bergamo Ovest,Comprehensive Cancer Center
[11] Fondazione Policlinico Universitario Agostino Gemelli,Medical Oncology
[12] IRCCS,Oncology Unit
[13] Università Cattolica del Sacro Cuore,Medical Oncology Unit
[14] AULSS6 Euganea,Medical Oncology Department
[15] IRCCS Santa Maria Nuova,Department of Oncology
[16] San Giuseppe Moscati Hospital,Department of Pneumology and Oncology
[17] ASST Lecco,Medical Oncology
[18] AORN dei Colli-Ospedale Monaldi,Medical Oncology Unit
[19] Clinical Cancer Center “Giovanni Paolo II” – IRCCS,Department of Clinical Science and Community, Section of Medical Statistics, Biometry and Epidemiology “G.A. Maccacaro”, Faculty of Medicine and Surgery
[20] University of Bari,Section of Oncology, Department of Medicine
[21] Policlinico di Bari,Clinical Medicine and Surgery Department
[22] University of Milan,undefined
[23] University and Hospital Trust of Verona,undefined
[24] University of Naples “Federico II”,undefined
来源：
BMC Cancer | / 22卷
关键词：
Cisplatin; Dexamethasone; NEPA; Quality of life; Functional living index-Emesis; Chemotherapy-induced nausea and vomiting (CINV);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy
    Nakashima, Kazuhisa
    Murakami, Haruyasu
    Yokoyama, Kouichi
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Nishiyama, Fumie
    Kikugawa, Mami
    Kaneko, Masayo
    Iwamoto, Yumiko
    Koizumi, Satomi
    Mori, Keita
    Isobe, Takeshi
    Takahashi, Toshiaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (09) : 840 - 843
  • [42] Phase II Study of Palonosetron, Aprepitant, Dexamethasone and Olanzapine for the Prevention of Cisplatin-Based Chemotherapy-Induced Nausea and Vomiting in Patients With Thoracic Malignancy
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (08) : 16 - 17
  • [43] Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies
    Schwartzberg, Lee
    Karthaus, Meino
    Rossi, Giorgia
    Rizzi, Giada
    Borroni, Maria E.
    Rugo, Hope S.
    Jordan, Karin
    Hansen, Vincent
    CANCER MEDICINE, 2019, 8 (05): : 2064 - 2073
  • [44] THE EFFICACY OF TRIPLET ANTIEMETIC THERAPY FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN LUNG CANCER PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY: PALONOSETRON (PALO), APREPITANT (APR), AND DEXAMETHASONE (DEX)
    Yoshizawa, H.
    Sato, K.
    Makino, M.
    Kobayashi, O.
    Tanaka, H.
    Miura, S.
    Watanabe, S.
    Tanaka, J.
    Kagamu, H.
    Ichiei, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 509 - 509
  • [45] A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy
    Osaki, Akihiko
    Inoue, Kenichi
    Sakai, Hiroshi
    Yamada, Kazuhiko
    Minato, Koichi
    Ohyanagi, Fumiyoshi
    Tokuda, Yutaka
    Ikeda, Norihiko
    Kagamu, Hiroshi
    Kubota, Kaoru
    Tamura, Tomohide
    Saeki, Toshiaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (02) : 121 - 129
  • [46] A MULTI-CYCLE PHASE III STUDY EVALUATING PALONOSETRON VERSUS ONDANSETRON AT PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING
    Kovacs, G.
    Wachtel, A.
    Basharova, E.
    Spinelli, T.
    Nicolas, P.
    Kabickova, E.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S167 - S167
  • [47] The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study
    Vaswani, Bharat
    Dattatreya, Palanki S.
    Barkate, Hanmant
    Bhagat, Sagar B.
    Patil, Saiprasad
    Jadhav, Amit Y.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
  • [48] A multicycle phase III study evaluating palonosetron vs ondansetron at preventing chemotherapy-induced nausea and vomiting in pediatric patients
    Kabickova, E.
    Wachtel, A.
    Basharova, E.
    Spinelli, T.
    Nicolas, P.
    Kovacs, G.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S237 - S237
  • [49] NEPA <sc>(</sc>Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial
    Navari, Rudolph M.
    Bonizzoni, Erminio
    CANCER MEDICINE, 2025, 14 (07):
  • [50] Risk factors of chemotherapy-induced nausea and vomiting during cisplatin regimen in antiemetic triplet regimen including palonosetron or granisetron: TRIPLE study (phase lll)
    Suzuki, K.
    Tsuji, D.
    Ito, K.
    Kawasaki, Y.
    Yamanaka, T.
    Hashimoto, H.
    Goto, K.
    Matsui, R.
    Seki, N.
    Hama, T.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2017, 28
12345